INDEX / DIRECTORY / TEVA PHARMACEUTICALS

Teva Pharmaceuticals🇮🇱

Pharmaceuticals 124 CITED SOURCES UPDATED 2026-09-22 METHOD V6.5
BDS-1000 Score 811 /1000 A Tier A - Extreme
Military ↗ 1.00 Digital ↗ 0.00 Economic ↗ 9.10 Political ↗ 8.50
OWNERSHIP TREE 31 brands and group businesses View all

OpenIntel is reader-funded - no sponsors, no institutional money. Support OpenIntel →

Key Findings

  • Economic: Teva is Israeli-incorporated and headquartered in Petah Tikva, with manufacturing, R&D and distribution operations in Israel; a 2024 tax settlement requires $750 million in payments to the Israel Tax Authority through 2029, plus a contingent payment tied to future dividends or buybacks.1, 2
  • Political: Teva’s 11 October 2023 statement declared that it “stands with Israel”; the reviewed record identified no comparable company statement addressing Palestinian civilian casualties, Gaza’s humanitarian conditions, or ICJ/ICC proceedings.3, 4
  • Military: Historical participation in the IDF-linked Adopt-a-Battalion welfare programme and post-7 October medicine/equipment donations are documented, but no verified Teva procurement contract or direct supply arrangement with the IDF or Israeli Ministry of Defense was identified.5, 6
  • Not found: No public evidence identified of Teva involvement in weapons systems, military-specific pharmaceutical products, Israeli defence-prime supply chains, offensive cyber capabilities, Project Nimbus, or surveillance technology supplied to Israeli security bodies.7, 8

Target Profile

FieldDetail
Company NameTeva Pharmaceutical Industries Limited
JurisdictionIsrael; Israeli-incorporated and Israeli-domiciled.1
HeadquartersPetah Tikva, Israel.1
SectorPharmaceutical manufacturing, generic, innovative and biosimilar medicines, active pharmaceutical ingredients, distribution, and related services.9
OwnershipPublicly traded on NASDAQ, NYSE, and the Tel Aviv Stock Exchange; no public evidence identified of Israeli state equity ownership.1, 10
Key Executives / GovernanceRichard D. Francis, President, CEO and director; Dr. Sol J. Barer, Board Chair. Current directors documented in Teva disclosures include Rosemary Crane, Amir Elstein, Chen Lichtenstein, Gerald Lieberman, Roberto Mignone, Perry Nisen, Ronit Satchi-Fainaro, and Tal Zaks.11, 12
Israeli-Nexus SummaryIsraeli-domiciled pharmaceutical group with substantial Israeli operations, historic Palestinian-market allegations, documented Israeli-state economic contribution, and limited but documented IDF-welfare and donation links; no verified direct Israeli defence-procurement relationship was identified.1, 5, 6

Key Facts:

Executive Summary

Teva Pharmaceutical Industries Limited is an Israeli-incorporated, Israeli-domiciled pharmaceutical group headquartered in Petah Tikva. Its documented Israel nexus is principally economic and institutional: it maintains manufacturing, R&D, logistics and distribution operations in Israel, including SLE’s Israeli distribution activity, and it has made substantial payments to the Israel Tax Authority under a 2024 settlement resolving tax years 2008–2020.1, 2, 13

The strongest evidence supporting the economic assessment concerns Teva’s ongoing Israeli operational footprint and fiscal contribution. Teva’s own filings place a small share of global revenue in its country of domicile, but the company remains an Israeli parent whose worldwide business is economically anchored there.1, 9 Historical civil-society research also describes Teva as benefiting from market asymmetries affecting Palestinian pharmaceutical producers under the Paris Protocol; however, that detailed research is dated to 2012, and a December 2024 KPMG review found no demonstrated presence, production, or other activity by Teva in occupied Palestinian areas.15, 6

The political record includes Teva’s public 11 October 2023 “Standing with Israel” statement, its documented partnership with Israeli state-linked vaccine-distribution infrastructure during the COVID-19 rollout, and historic or post-7 October support connected to IDF reservists and soldier-welfare programmes.3, 16, 5 These facts establish political and institutional alignment with Israel and documented support channels, but do not establish that Teva manufactures weapons or holds a verified defence-procurement contract.

The military evidence is limited and must be read with care. Teva was historically named in relation to the IDF-linked Adopt-a-Battalion programme, and its 2023 ESG reporting describes donations through Le’Rufuah to soldiers, victims, evacuees and others in need.5, 17 Available evidence characterises these as welfare support and donations rather than procurement; no public evidence identified of a verified Teva contract, tender award, framework agreement, or named Medical Corps procurement instrument with the IDF, Israeli Ministry of Defense, Border Police, or Israel Prison Service.6, 18

No public evidence identified of Teva’s participation in weapons production, military systems, defence-prime component supply, offensive cyber operations, Project Nimbus, or the sale of surveillance technology to Israeli state bodies.7, 8 The fixed, human-vetted V6.5 result is therefore driven by the documented economic and political nexus rather than by a proven military-industrial or digital-security role: BRS 811, Tier A (Extreme Complicity).

Timeline of Relevant Events

DateEvent
1901Teva traces its origins to the Jerusalem wholesale-drug business SLE Ltd., named for Chaim Salomon, Moshe Levin and Yitschak Elstein.10
1976Teva Pharmaceutical Industries Ltd. was formed through the merger of three Israeli pharmaceutical companies.10
2012Who Profits published its “Captive Economy” pharmaceutical-sector analysis, describing structural Palestinian-market advantages for Israeli pharmaceutical companies including Teva.15
2014Teva was named among donors to the IDF Association for the Wellbeing of Israel’s Soldiers’ Adopt-a-Battalion programme; participation involved three-year commitments to combat-unit welfare budgets and equipment.5, 19
2016Reporting documented that former Teva subsidiary MBT Biological Laboratories had left the Atarot industrial zone for Beit Shemesh; the exact relocation date was not established.20
2019Teva sold the Shoham logistics facility to Amot Investments and SLE leased it back under a 10-year arrangement.14
11 October 2023Teva Pharmaceuticals USA issued its “Standing with Israel” statement after the 7 October attacks.3
October 2023Teva stated that it worked through Le’Rufuah to donate medicines and medical equipment for soldiers, victims, evacuees and others in need.17
February 2024CEO Richard Francis said Israeli production and distribution had remained largely unaffected by wartime conditions.21
June 2024Teva agreed to a settlement with the Israel Tax Authority involving $750 million in scheduled payments and a contingent additional amount related to future dividends or buybacks.2
December 2024KPMG’s targeted research for Norway’s Sykehusinnkjøp found no demonstrated Teva presence, production, or other activity in occupied Palestinian areas.6
March 2025Sykehusinnkjøp recommended against terminating its contracts with Teva Norway AS.22
November 2025Teva launched the Rise open-innovation platform with the Israel Innovation Authority and Startup Nation Central.23

Corporate Overview

Teva is a publicly traded Israeli pharmaceutical parent company. Its disclosed business includes generic, innovative and biosimilar medicines; APIs; contract manufacturing; product distribution; and out-licensing. Its business disclosures do not describe weapons manufacture, military hardware, surveillance products, or defence-system integration.9

Teva’s Israeli operational structure includes SLE, a wholly controlled Israeli subsidiary that distributes Teva and third-party pharmaceutical products. Historical descriptions identify SLE as an Israeli and Palestinian-market distribution unit; current company disclosures establish its continuing group status and Israeli distribution role, but do not identify current OPT routes, settlement destinations, military end-users, or end-use controls.13, 15

Israeli facilities documented across the audits include manufacturing or R&D activity in Kfar Saba, Neot Hovav and Netanya, as well as the Shoham logistics centre. The Shoham property was sold in 2019 and leased back by Teva/SLE; the landlord’s separate ownership of an Ariel settlement asset does not establish Teva ownership, use, or operation of that settlement asset.14, 24

The historical MBT Biological Laboratories issue requires a narrow attribution. Available reporting indicates that MBT previously operated at Atarot before relocating to Beit Shemesh, with the operation discontinued there no later than 2016. KPMG noted that entity attribution and underlying evidence around related claims were not widely corroborated. This record is not treated as evidence of a current Teva settlement facility.20, 6

Domain Summaries

Military: Military

Mechanism of Involvement

Teva was named in historical material as a donor to the IDF-linked Adopt-a-Battalion programme. The programme’s description provides for corporate commitments to welfare budgets and equipment for combat units. KPMG’s December 2024 research reported that Teva was no longer listed as an active programme partner; the end date and any later participation were not established.5, 19, 6

After 7 October 2023, Teva reported donating medicines and medical equipment through Le’Rufuah for “soldiers, victims, those evacuated from their homes or others in need.” Reporting also described donations of medicines, baby-food compounds and computers associated with the IDF response. The available record does not establish precise recipients, quantities, dates, or whether goods entered military rather than civilian medical channels.17, 25

SLE’s continuing Israeli distribution role establishes civilian pharmaceutical distribution activity, not military logistics. Teva’s filings acknowledge regional military activity and employee reservist call-ups as operational risks, but do not establish a supply relationship with the Israeli armed forces.13, 26

Counter-Arguments and Evidence Limits

No public evidence identified of a verified Teva contract, tender award, framework agreement, memorandum of understanding, or named procurement instrument with the Israeli Ministry of Defense, IDF, Border Police, or Israel Prison Service.6, 18 A 2025 Ministry of Defense request for information concerning medicines and medical equipment did not name Teva as a respondent or awardee.18

No public evidence identified that Teva makes military-specific, ruggedised, tactical or defence-grade pharmaceutical products; its published portfolio is ordinary pharmaceutical production. Standard medicines may be usable by military medical services, but the reviewed record identifies no Teva military specification, Israeli security end-user arrangement, contract modification, export licence, or end-user certificate.9, 6

Teva Pharmaceuticals USA has documented U.S. Department of Defense vaccine-contract activity. This concerns a U.S. DoD customer, not an Israeli defence end-user, and is not evidence of Israeli military procurement.27

Named Entities and Evidence Map

Digital: Digital

Mechanism of Involvement

Teva operates ordinary enterprise and health-related digital systems. Its Digihaler platform uses AWS cloud infrastructure, and Teva has used SAP SuccessFactors for global HR and Accenture for certain pharmacovigilance data-processing functions.28, 29, 30 Its privacy notices describe cross-border processing, including processing in Israel, India and the United States.30, 31

Teva is a founding pharmaceutical partner of AION Labs, an Israeli AI drug-discovery venture studio, and is a named partner in the Israel BioToken Factory Initiative, a civilian biomedical AI-infrastructure consortium. The audits identify biomedical drug-discovery and clinical-decision-support applications, not targeting, kill-chain, military decision-support, or surveillance use.32, 33

Counter-Arguments and Evidence Limits

No public evidence identified of Teva’s direct participation in Project Nimbus; no public evidence identified that Teva supplies sovereign-cloud, security, surveillance, or data-resilience services to Israeli state or military institutions.8, 31

No public evidence identified of direct technology contracts with the Israeli Ministry of Defense, IDF or intelligence agencies; of offensive cyber products; of digital-weapons systems; or of Teva AI models trained on intercepted communications, surveillance data, or occupied-territory population datasets.8, 33

The audits also found no public evidence of direct Teva relationships with named Israeli cybersecurity vendors such as Check Point, Wiz, SentinelOne, CyberArk, NICE, Verint or Claroty. This is an absence from publicly available material, not proof that no vendor relationship exists.34, 35

Named Entities and Evidence Map

Economic: Economic

Mechanism of Involvement

Teva’s strongest documented nexus is economic. It is Israeli-incorporated, Israeli-domiciled and headquartered in Petah Tikva, with manufacturing, R&D, logistics and distribution operations in Israel. Israel represented approximately 2% of consolidated revenue in fiscal years 2022–2025, while production and corporate activity remain materially rooted in Israel.1, 9, 21

Teva reached a 2024 settlement with the Israel Tax Authority requiring $750 million in payments from 2024 through 2029, plus a contingent additional payment linked to future dividends or buybacks and capped at approximately $500 million. This resolved a long-running dispute covering tax years 2008–2020 and constitutes a documented fiscal contribution to the Israeli state.2

Historical Who Profits and AFSC material describes Teva as benefiting from a Palestinian “captive market” under the Paris Protocol: access to Palestinian markets without customs or checkpoint barriers, while Palestinian producers faced regulatory and export obstacles. Those detailed claims derive principally from 2012 material and should not be treated as standalone verification of current practices.15, 36

Counter-Arguments and Evidence Limits

KPMG’s December 2024 targeted research found no demonstrated Teva presence, production or other activity in occupied Palestinian areas, and no clear and unambiguous evidence that Teva benefits from Israel’s discriminatory trade policy toward Palestinians. Sykehusinnkjøp subsequently recommended against terminating its Teva Norway contracts.6, 22

No public evidence identified that Teva directly owns or operates a current settlement facility, or that it holds or uses the Ariel industrial property separately owned by its Shoham landlord. No public evidence identified of Teva product-mislabeling findings by customs or regulatory authorities, nor of a Teva-specific occupied-territory sourcing policy.24, 6

Teva was not included in the final 2020 OHCHR settlement-business database publication and remained unlisted in the September 2025 update. These are document-scoped absences, not proof that all possible settlement-related nexus is absent.37, 38

Named Entities and Evidence Map

Political: Political

Mechanism of Involvement

On 11 October 2023, Teva issued a public statement declaring that it “stands with Israel” following the 7 October attacks. The statement did not address Palestinian civilians, and the audit identified no later Teva statement, press release or executive comment addressing Palestinian civilian casualties, Gaza’s humanitarian conditions, or ICJ/ICC proceedings.3, 4

Teva has documented relationships with Israeli state institutions and public infrastructure. During the COVID-19 rollout, Teva/Teva-SLE served as the Israeli government’s exclusive in-country logistics and distribution partner for Pfizer vaccines, using ultra-cold-chain infrastructure to distribute vaccines to approximately 400 sites.16, 39

The political record also includes historic Adopt-a-Battalion participation, employee equipment collections for the IDF in October 2023, and Teva funding of professional supervision through the “Support the Soul” initiative with organisations supporting IDF combat-soldier mental health. These support channels are documented, although they are distinct from procurement or weapons supply.5, 40, 25

Counter-Arguments and Evidence Limits

No public evidence identified of Teva or its executives holding leadership roles in AIPAC, CFI, ADL, USISTF or similar advocacy organisations; nor of corporate anti-BDS lobbying activity. Disclosed U.S. and EU lobbying related to pharmaceutical pricing, intellectual property, health policy, generics and supply-chain issues, rather than Israel/Palestine policy.41, 42, 43

No public evidence identified of Teva employee discipline for pro-Palestinian expression, content moderation controversies, or formal shareholder resolutions specifically addressing Israel-Palestine human-rights due diligence.44

Teva’s strongest stated defence to boycott pressure is a patient-access and humanitarian framing. Its public responses have stressed medicine availability and healthcare savings rather than accepting underlying political allegations. Teva-donated medicines have also been included in Direct Relief humanitarian shipments into Gaza, alongside donations from other manufacturers.45, 46

Named Entities and Evidence Map

BDS-1000 Score

Method: V6.5.

DomainIMPV-Domain Score
Military2.502.809.001.00
Digital0.000.000.000.00
Economic9.108.709.009.10
Political8.507.009.008.50

The V_MAX is driven by Teva’s direct Israeli economic footprint: Israeli domicile, operating infrastructure, tax settlement and continuing institutional economic integration. The political score reflects public alignment, state-linked logistics, and documented soldier-welfare support. The score is scale-free, evidence-only, and fixed after human vetting; it does not convert unverified claims, divested operations, wrong-entity allegations, or document-scoped absences into stronger findings.

Methodology Note

Footnotes

  1. https://www.tevapharm.com/our-company/teva-history/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10

  2. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2024/Teva-Reaches-Agreement-With-the-Israel-Tax-Authority-to-Resolve-All-Pending-Litigation-for-the-Companys-Taxable-Years-2008-2020/default.aspx ↩ ↩2 ↩3 ↩4 ↩5

  3. https://www.marketscreener.com/quote/stock/TEVA-PHARMACEUTICAL-INDUS-40246797/news/Standing-with-Israel-Teva-Statement-Regarding-the-Attacks-on-Israel-and-Israeli-Civilians-45041211/ ↩ ↩2 ↩3 ↩4 ↩5

  4. https://www.timesofisrael.com/teva-ceo-says-production-and-distribution-in-israel-remain-largely-unaffected-by-war/ ↩ ↩2

  5. https://stopteva.nl/wp-content/uploads/2025/07/20250615_Teva_and_the_IDF_Repill-.pdf ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

  6. https://www.sykehusinnkjop.no/4b01f0/siteassets/bilder/nyheter/2024/gransking-teva/kpmg-targeted-research-teva-december-2024.pdf ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14

  7. https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612d10k.htm ↩ ↩2

  8. https://www.ohchr.org/en/documents/hr-bodies/hrc/sp-sessions/A-HRC-59-23-en ↩ ↩2 ↩3 ↩4

  9. https://www.sec.gov/Archives/edgar/data/818686/000119312525020826/d865574d10k.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  10. https://www.tevapharm.com/our-company/teva-history/ ↩ ↩2 ↩3

  11. https://www.tevapharm.com/our-company/leadership-governance/corporate-executives ↩

  12. https://www.tevapharm.com/our-company/leadership-governance/board-of-directors ↩

  13. https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612dex21.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  14. https://www.fiercepharma.com/pharma/teva-sheds-logistics-center-for-127m-after-2-years-2-about-faces ↩ ↩2 ↩3

  15. https://www.whoprofits.org/writable/uploads/publications/1668626890_1aa4455a6a4cc3b32b5d.pdf ↩ ↩2 ↩3 ↩4 ↩5

  16. https://en.globes.co.il/en/article-teva-readying-to-distribute-covid19-vaccine-in-israel-1001351925 ↩ ↩2 ↩3

  17. https://www.tevapharm.com/globalassets/tevapharm-vision-files/teva-esg-progress-report-2023.pdf ↩ ↩2 ↩3 ↩4 ↩5

  18. https://www.online.mod.gov.il/Online2016/pages/general/News/SingleMessage.aspx?id=464&tType=1 ↩ ↩2 ↩3 ↩4

  19. https://www.idf.il/98093/ ↩ ↩2 ↩3 ↩4

  20. https://www.haaretz.com/israel-news/2016-03-27/ty-article/.premium/israeli-firms-increasingly-leaving-west-bank/0000017f-df01-db5a-a57f-df6bd8b60000 ↩ ↩2

  21. https://www.timesofisrael.com/teva-ceo-says-production-and-distribution-in-israel-remain-largely-unaffected-by-war/ ↩ ↩2 ↩3

  22. https://www.sykehusinnkjop.no/nyheter/nyheter-2025/anbefaler-ikke-a-avslutte-kontrakter-med-teva/ ↩ ↩2 ↩3 ↩4

  23. https://www.tevapharm.com/news-and-media/latest-news/teva-launches-rise-a-global-open-innovation-platform-to-accelerate-ai-industry-4.0-smart-manufacturing ↩

  24. https://investigate.afsc.org/company/amot-investments ↩ ↩2

  25. https://www.declassifieduk.org/the-israeli-firm-aiding-the-nhs-and-idf/ ↩ ↩2

  26. https://www.sec.gov/Archives/edgar/data/818686/000119312525020826/d865574d10k.htm ↩

  27. https://www.govchime.com/market-intelligence/awards/CONT_AWD_SPE2DP25F4433_9700_SPE2DP20D0002_9700 ↩

  28. https://www.tevausa.com/news-and-media/press-releases/teva-amazon-web-services-and-onica-announce-collaboration-to-support-tevas-digihaler-portfolio/ ↩ ↩2

  29. https://www.computerweekly.com/news/450428023/Teva-Pharmaceuticals-turns-to-cloud-HR-as-it-weathers-difficult-trading-conditions ↩ ↩2

  30. https://www.tevapharm.com/our-company/corporate-governance/teva-privacy-notice/ ↩ ↩2 ↩3

  31. https://www.tevauk.com/privacy-policy/ ↩ ↩2

  32. https://aws.amazon.com/blogs/industries/aws-joins-pharma-and-biotech-leaders-in-launching-aion-labs-to-transform-therapeutics/ ↩ ↩2

  33. https://natlawreview.com/press-releases/israel-innovation-authority-invests-approx-nis-70-million-national ↩ ↩2 ↩3

  34. https://www.board-cybersecurity.com/annual-reports/tracker/20250205-teva-pharmaceutical-industries-ltd-cybersecurity-10k ↩

  35. https://www.upguard.com/security-report/teva-pharmaceutical-industries ↩

  36. https://investigate.afsc.org/company/teva-pharmaceutical-indus ↩ ↩2

  37. https://www.ohchr.org/en/pages/business-involved-israeli-settlements ↩

  38. https://www.ohchr.org/en/press-releases/2025/09/un-human-rights-office-updates-database-businesses-involved-israeli ↩

  39. https://www.timesofisrael.com/at-vaccine-deepfreeze-storage-site-netanyahu-says-end-of-virus-crisis-in-sight/ ↩ ↩2

  40. https://www.ufis.org.il/en/activity/adopt-a-combat-battalion/ ↩ ↩2

  41. https://www.opensecrets.org/orgs/teva-pharmaceutical-industries/summary?id=D000029389 ↩

  42. https://www.fec.gov/data/committee/C00434811/ ↩

  43. https://www.lobbyfacts.eu/datacard/teva-pharmaceuticals-europe-bv?rid=27116427434-57 ↩

  44. https://actionnetwork.org/petitions/letter-to-un-global-compact-for-removal-of-teva-pharmaceuticals-from-list-of-participants ↩

  45. https://www.jpost.com/diaspora/antisemitism/article-865087 ↩

  46. https://www.directrelief.org/2024/05/direct-relief-delivers-humanitarian-aid-into-gaza/ ↩ ↩2